Biokinetics and Dosimetry of Commonly Used Radiopharmaceuticals in Diagnostic Nuclear Medicine - a Review

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2011 Aug 31

PMID 21877166

Citations 16

Authors

Uta Eberlein

Jorn Hendrik Broer

Charlot Vandevoorde

Paula Santos

Manuel Bardies

Klaus Bacher

Dietmar Nosske

Michael Lassmann

Affiliations

Soon will be listed here.

Abstract

Purpose: The impact on patients' health of radiopharmaceuticals in nuclear medicine diagnostics has not until now been evaluated systematically in a European context. Therefore, as part of the EU-funded Project PEDDOSE.NET ( www.peddose.net ), we review and summarize the current knowledge on biokinetics and dosimetry of commonly used diagnostic radiopharmaceuticals.

Methods: A detailed literature search on published biokinetic and dosimetric data was performed mostly via PubMed ( www.ncbi.nlm.nih.gov/pubmed ). In principle the criteria for inclusion of data followed the EANM Dosimetry Committee guidance document on good clinical reporting.

Results: Data on dosimetry and biokinetics can be difficult to find, are scattered in various journals and, especially in paediatric nuclear medicine, are very scarce. The data collection and calculation methods vary with respect to the time-points, bladder voiding, dose assessment after the last data point and the way the effective dose was calculated. In many studies the number of subjects included for obtaining biokinetic and dosimetry data was fewer than ten, and some of the biokinetic data were acquired more than 20 years ago.

Conclusion: It would be of interest to generate new data on biokinetics and dosimetry in diagnostic nuclear medicine using state-of-the-art equipment and more uniform dosimetry protocols. For easier public access to dosimetry data for diagnostic radiopharmaceuticals, a database containing these data should be created and maintained.

Citing Articles

Future Prospective of Radiopharmaceuticals from Natural Compounds Using Iodine Radioisotopes as Theranostic Agents.

Nurhidayah W, Setyawati L, Daruwati I, Gazzali A, Subroto T, Muchtaridi M Molecules. 2022; 27(22).

PMID: 36432107 PMC: 9694974. DOI: 10.3390/molecules27228009.

How can we optimise the pharmaceutical analysis of radiopharmaceutical pediatric prescriptions?.

Leclerc P, Marie S, Fouque J, Olivier M, Blondeel-Gomes S Eur J Hosp Pharm. 2021; 30(1):29-34.

PMID: 33962998 PMC: 9811567. DOI: 10.1136/ejhpharm-2020-002473.

EANM position paper on the role of radiobiology in nuclear medicine.

Aerts A, Eberlein U, Holm S, Hustinx R, Konijnenberg M, Strigari L Eur J Nucl Med Mol Imaging. 2021; 48(11):3365-3377.

PMID: 33912987 PMC: 8440244. DOI: 10.1007/s00259-021-05345-9.

Species Differences in Microsomal Metabolism of Xanthine-Derived A Adenosine Receptor Ligands.

Schneider D, Bier D, Holschbach M, Bauer A, Neumaier B Pharmaceuticals (Basel). 2021; 14(3).

PMID: 33803861 PMC: 8003343. DOI: 10.3390/ph14030277.

SOLLID - a single centre study to develop methods to investigate the effects of low radiation doses within nuclear medicine, to enable multicentre epidemiological investigations.

Flux G, Murray I, Rushforth D, Gape P, Abreu C, Lee M Br J Radiol. 2020; 94(1119):20200072.

PMID: 32903035 PMC: 8011250. DOI: 10.1259/bjr.20200072.

References

Hays M, Berman M . Pertechnetate distribution in man after intravenous infusion: a compartmental model. J Nucl Med. 1977; 18(9):898-904. View

Siegel J, Thomas S, STUBBS J, Stabin M, Hays M, Koral K . MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999; 40(2):37S-61S. View

Booij J, Busemann Sokole E, Stabin M, Janssen A, De Bruin K, van Royen E . Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med. 1998; 25(1):24-30. View

Niven E, Nahmias C . Absorbed dose to very low birth weight infants from 18F-fluorodeoxyglucose. Health Phys. 2003; 84(3):307-16. DOI: 10.1097/00004032-200303000-00003. View

Roivainen A, Forsback S, Gronroos T, Lehikoinen P, Kahkonen M, Sutinen E . Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med. 2000; 27(1):25-32. DOI: 10.1007/pl00006658. View

Bajc M, Palmer J, Ohlsson T, Edenbrandt L . Distribution and dosimetry of 111In DTPA-D-Phe-octreotide in man assessed by whole body scintigraphy. Acta Radiol. 1994; 35(1):53-7. View

Ruotsalainen U, Eronen E, Kinnala A, Bergman J, Haaparanta M, Teras M . Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med. 1996; 37(2):387-93. View

Kearfott K . Radiation absorbed dose estimates for positron emission tomography (PET): K-38, Rb-81, Rb-82, and Cs-130. J Nucl Med. 1982; 23(12):1128-32. View

. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007; 37(2-4):1-332. DOI: 10.1016/j.icrp.2007.10.003. View

10.

Hays M, Watson E, Thomas S, Stabin M . MIRD dose estimate report no. 19: radiation absorbed dose estimates from (18)F-FDG. J Nucl Med. 2002; 43(2):210-4. View

11.

. MIRD/Dose Estimate Report No. 8. Summary of current radiation dose estimates to normal humans from 99mTc as sodium pertechnetate. J Nucl Med. 1976; 17(1):74-7. View

12.

. Mird-dose estimate report no. 2. Summary of current radiation dose estimates to humans from 66Ga-, 68Ga-, and 72Ga-citrate. J Nucl Med. 1973; 14(10):755-6. View

13.

Wackers F, Berman D, Maddahi J, WATSON D, Beller G, Strauss H . Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med. 1989; 30(3):301-11. View

14.

Khamwan K, Krisanachinda A, Pasawang P . The determination of patient dose from (18)F-FDG PET/CT examination. Radiat Prot Dosimetry. 2010; 141(1):50-5. DOI: 10.1093/rpd/ncq140. View

15.

Stabin M . Proposed revision to the radiation dosimetry of 82Rb. Health Phys. 2010; 99(6):811-3. DOI: 10.1097/HP.0b013e3181e47b33. View

16.

Becker W, Borst U, Fischbach W, Pasurka B, Schafer R, Borner W . Kinetic data of in-vivo labeled granulocytes in humans with a murine Tc-99m-labelled monoclonal antibody. Eur J Nucl Med. 1989; 15(7):361-6. DOI: 10.1007/BF00449225. View

17.

Thomas S, Stabin M, Castronovo F . Radiation-absorbed dose from 201Tl-thallous chloride. J Nucl Med. 2005; 46(3):502-8. View

18.

Helisch A, Forster G, Reber H, Buchholz H, Arnold R, Goke B . Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004; 31(10):1386-92. DOI: 10.1007/s00259-004-1561-6. View

19.

. Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP. 2000; 28(3):1-126. DOI: 10.1016/s0146-6453(99)00006-8. View

20.

van den Hoff J, Burchert W, Wolpers H, Meyer G, Hundeshagen H . A kinetic model for cardiac PET with [1-carbon-11]-acetate. J Nucl Med. 1996; 37(3):521-9. View